Premium
Pharmacogenomics: “Noninferiority” Is Sufficient for Initial Implementation
Author(s) -
Altman RB
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2010.310
Subject(s) - pharmacogenomics , clinical pharmacology , pharmacogenetics , medicine , computer science , medical physics , computational biology , pharmacology , biology , genetics , genotype , gene
Recent clinical annotation of a whole‐genome sequence suggests that pharmacogenomics (PGx) may be ready for clinical implementation now. This conclusion rests on the recognition that PGx has greatly mitigated risks as compared with using genomics for assessment of disease risk. Failure to recognize these differences can produce unrealistic cost–benefit scenarios and impractical standards of evidence. In many cases, pharmacogenetic tests need only reach reasonable expectations of noninferiority (compared with current prescribing practices) to merit use. Clinical Pharmacology & Therapeutics (2011) 89 3, 348–350. doi: 10.1038/clpt.2010.310